Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof

A method of treating psoriasis comprising orally administering a tablet to a subject in need thereof, wherein the tablet comprises:

• (A) a core comprising (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate in a dose of about 100 mg or about 200 mg;
• and
• (B) a compressed coating layer surrounding the tablet core, wherein the compressed coating layer
• (i) comprises hydroxypropyl methyl cellulose;
• and
• (ii) is substantially free of ionizable polymer having carboxylic acid moieties;
• wherein (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is the sole active ingredient in the tablet;
• wherein the tablet, when subjected to an aqueous solution free of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, releases at most 20% of the (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate from the core over a period of 2 hours.